Payment overview · 2025
General Payments
$94.87
4 reported records · 4 companies
Healthcare provider profile · identity verified
Luis G Schaeffer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, TX · NPI 1376586230
Verified facts
What the public records show
CMS Open Payments records show Luis G Schaeffer, M.D. received $94.87 in general payments during 2025 across 4 reported records.
Inspire Medical Systems, Inc. accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $38.33 | 40.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.54 | 21.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.57 | 19.6% | 1 | 2025 |
| OWP Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.43 | 18.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.87 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $38.33 | 1 | 2025 |
Source payment records
|
|||||
| Subvenite Normalized: subvenite |
Drug | OWP Pharmaceuticals, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 766 | 276 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 469 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 134 |
| Metformin Hcl | Metformin Hcl | 411 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 139 |
| Lisinopril | Lisinopril | 341 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 300 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 63 |
| Gabapentin | Gabapentin | 280 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 248 | 85 |
| Furosemide | Furosemide | 243 | 84 |
| Losartan Potassium | Losartan Potassium | 242 | 81 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 218 | 56 |
| Naproxen | Naproxen | 215 | 87 |
| Alprazolam | Alprazolam | 189 | 25 |
| Lorazepam | Lorazepam | 184 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 61 |
| Prednisone | Prednisone | 174 | 110 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 163 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 50 |
| Ozempic | Semaglutide | 145 | 32 |
| Omeprazole | Omeprazole | 141 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 47 |
| Trazodone Hcl | Trazodone Hcl | 139 | 34 |
| Clonidine Hcl | Clonidine Hcl | 136 | 49 |
| Carvedilol | Carvedilol | 115 | 38 |
| Sertraline Hcl | Sertraline Hcl | 110 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 109 | 42 |
| Meloxicam | Meloxicam | 104 | 40 |
| Nifedipine Er | Nifedipine | 104 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 39 |
| Tramadol Hcl | Tramadol Hcl | 102 | 20 |
| Potassium Chloride | Potassium Chloride | 100 | 38 |
| Glipizide | Glipizide | 97 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 43 |
| Allopurinol | Allopurinol | 93 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 33 |
| Simvastatin | Simvastatin | 88 | 24 |
| Eliquis | Apixaban | 87 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 84 | 33 |
| Clonazepam | Clonazepam | 80 | 11 |
| Glimepiride | Glimepiride | 80 | 27 |
| Ezetimibe | Ezetimibe | 79 | 28 |
| Mirtazapine | Mirtazapine | 79 | 28 |
| Azithromycin | Azithromycin | 74 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 26 |
| Baclofen | Baclofen | 72 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 19 |
| Montelukast Sodium | Montelukast Sodium | 60 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 17 |
| Atenolol | Atenolol | 57 | 17 |
| Buspirone Hcl | Buspirone Hcl | 55 | 11 |
| Trulicity | Dulaglutide | 54 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 12 |
| Lovastatin | Lovastatin | 51 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 13 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 15 |
| Meclizine Hcl | Meclizine Hcl | 48 | 21 |
| Famotidine | Famotidine | 47 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 19 |
| Fenofibrate | Fenofibrate | 45 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 19 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Finasteride | Finasteride | 40 | 14 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 14 |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | 11 |
| Levofloxacin | Levofloxacin | 32 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 14 |
| Cephalexin | Cephalexin | 23 | 18 |
| Temazepam | Temazepam | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 15 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 17 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.87 · 4 records | Inspire Medical Systems, Inc. | INSPIRE, Subvenite | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error